COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP was written by Busca, Alessandro;Salmanton-Garcia, Jon;Corradini, Paolo;Marchesi, Francesco;Cabirta, Alba;Di Blasi, Roberta;Dulery, Remy;Lamure, Sylvain;Farina, Francesca;Weinbergerova, Barbora;Batinic, Josip;Nordlander, Anna;Lopez-Garcia, Alberto;Drgona, Lubos;Espigado-Tocino, Ildefonso;Falces-Romero, Iker;Garcia-Sanz, Ramon;Garcia-Vidal, Carolina;Guidetti, Anna;Khanna, Nina;Kulasekararaj, Austin;Maertens, Johan;Hoenigl, Martin;Klimko, Nikolai;Koehler, Philipp;Pagliuca, Antonio;Passamonti, Francesco;Cornely, Oliver A.;Pagano, Livio. And the article was included in Blood Advances in 2022.Reference of 16506-27-7 The following contents are mentioned in the article:
The aim of this study was to describe the clin. outcomes of patients developing COVID-19 after treatment with CAR T cells. In this retrospective observational multicenter study, collected data on all consecutive adult patients who received CAR T-cell therapy with symptomatic COVID-19 between Jan. 2020 and Feb. 2021 across 18 European centers (Spain, n = 6; France, n = 3; Italy, n = 2; and Belgium, Croatia, Czechia, Slovakia, Sweden, Switzerland, and the United Kingdom, n = 1 each) participating in the survey promoted by the European Hematol. Association (EHA) Scientific Working Group on Infection in Hematol. (EPICOVI- DEHA survey), developed by the EHA Infectious Diseases Working Party (IDWP). Patients received CAR T cells for the treatment of large B-cell lymphoma (n 5 28), multiple myeloma (n 5 1), and acute lymphoblastic leukemia (n 5 1). CAR T cells were tisagenlecleucel (Kymriah) in 16 cases and axicabtagene (Yescarta) in 13 cases, and 1 patient with multiple myeloma was treated with CAR T cells targeting B-cell maturation antigen. Median time from CAR T-cell treatment to COVID-19 diagnosis was 169 days (IQR, 37-313; range, 1-635). Cellular and humoral immune reconstitution after CAR T cells showed that 90 days after infusion, median absolute neutrophil count and absolute lymphocyte count (ALC) were 1700/mm3 and 435/mm3 resp., whereas at the time of COVID-19 diagnosis, median absolute neutrophil count and ALC were 925/mm3 and 370/mm3 resp. In total, 13 patients (43.3%) required admission to ICU after COVID-19, and 9 of them (66.7%) required mech. ventilation. Patients received treatment for COVID-19 according to local policy; 15 patients were treated with convalescent plasma alone (n = 3) or convalescent plasma combined with remdesivir with or without steroids (n = 8), remdesivir with lopinavir/ritonavir and steroids (n = 1), and tocilizumab and steroids (n = 3); 5 patients were treated with steroids alone (n = 4) or steroids combined with remdesivir and tocilizumab (n = 1); 1 patient was treated with azithromycin; and patient was treated with remdesivir alone. Severe (grade > 3) CRS after CAR T cells was observed in 1 patient only, and in total, 8 (53.3%) of 15 patients who developed CRS after CAR T-cell infusion required treatment with tocilizumab with or without steroids. Therapeutic strategies will need to be developed to ensure that CAR T-cell therapy can be delivered safely and successfully while COVID-19 remains endemic. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Reference of 16506-27-7).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Reference of 16506-27-7
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem